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Obesity is responsible for ~90,000 cancer deaths/year, increasing cancer incidence and
impairing its treatment. Obesity has also been shown to impact hematological malignan-
cies, through as yet unknown mechanisms. Adipocytes are present in bone marrow and
the microenvironments of many types of cancer, and have been found to promote cancer
cell survival. In this review, we explore several ways in which obesity might cause leukemia
treatment resistance. Obese patients may be at a treatment disadvantage due to altered
pharmacokinetics of chemotherapy and dosage “capping” based on ideal body weight.
The adipose tissue provides fuel to cancer cells in the form of amino acids and free fatty
acids. Adipocytes have been shown to cause cancer cells to resist chemotherapy-induced
apoptosis. In addition, obese adipose tissue is phenotypically altered, producing a milieu
of pro-inflammatory adipokines and cytokines, some of which have been linked to cancer
progression. Given the prevalence of obesity, understanding its role and adipose tissue
in acute lymphoblastic leukemia treatment is necessary for evaluating current treatment
regimen and revealing new therapeutic targets.
Keywords: adipocytes, tumor microenvironments, leukemia, pharmacokinetics, obesity, lipolysis, apoptosis, drug
resistance
INTRODUCTION
Obesity is a serious health problem in both adults and children.
Data from the National Health and Nutrition Examination Sur-
vey of 2009–2010 revealed that more than 35% of adults and
almost 17% of youth were obese1 in the United States (1). Another
one-third of adults and one-sixth of children are overweight,
meaning that overall most adults and about a third of children
have unhealthy weight. The estimated annual medical cost of
obesity in the U.S. was $209.7 billion, or $2741 for each obese
person (2). Obesity is associated with a variety of health con-
ditions, including type II diabetes (3), cardiovascular diseases,
hypertension, osteoarthritis, and cancer (4). However, the mecha-
nism(s) whereby obesity increases cancer incidence and mortality
are largely unknown.
There is now increased understanding that the cancer microen-
vironment plays an important role in spread, metastasis, and
treatment response. This microenvironment consists of cancer
cells, normal cells, and the intracellular matrix and signals sur-
rounding them. In solid tumors, cancer cells interact with several
types of host cells including fibroblasts, macrophages, lympho-
cytes, endothelial cells, and adipocytes. Through a complex set of
interactions, which are not completely understood, these host cells
are recruited to transform the local environment into a hospitable
1Obesity is defined by the Center for Disease Control as a body mass index (BMI)
≥30 kg/m2 in adults or ≥95th percentile in children. Overweight is considered a
BMI ≥25 but <30 kg/m2 in adults, and ≥85th but <95th percentile in children.
niche, improving access to nutrients, protecting from immune sur-
veillance, and providing growth factors and survival signals (5).
Together, these changes allow the cancer to survive, proliferate,
and metastasize (6). Given their mobile nature and propensity
to travel throughout the body, leukemia cells are exposed to
several microenvironments, including the bone marrow, spleen,
lymphatic system, the intravascular environment, and various
extramedullary tissues. Understanding the roles of these various
microenvironments is important for further improving treatment
outcome.
Adipose tissue and adipocytes have been shown to play an
important role in supporting progression of several types of can-
cer. Bone marrow, a major site of metastasis for solid tumors and
an important microenvironment for hematological malignancies,
is also rich in adipocytes. In fact, after induction chemotherapy for
acute lymphoblastic leukemia (ALL), adipocytes can represent the
primary cellular component of bone marrow (Figure 1). Given the
effects of obesity on cancer prognosis, we and others have investi-
gated whether these fat cells may contribute to treatment resistance
in leukemias and other cancers. The goal of this mini review is to
summarize our current understanding on how obesity/adipose
tissue contributes to leukemia relapse and drug resistance.
DOES OBESITY DIRECTLY INCREASE LEUKEMIA MORTALITY?
Obesity is strongly associated with increased cancer incidence and
mortality. A large prospective study published in 2003 by Eugenia
Calle and colleagues was one of the first to show that increased
BMI is associated with increased mortality from many types of
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FIGURE 1 | Representative bone marrow biopsies from a patient with
childhoodALL before (left) and after (right) induction chemotherapy.
Picture taken by Hiro Shimada (Wright-Giemsa stain, magnified 200×).
cancer (7). The study found an overall 52% increased mortal-
ity in men with BMI ≥35, and an 88% increase in women of
the same BMI category. While much of this increase in mortality
can be attributed to increased cancer incidence, obesity has also
been shown to associate with a poorer prognosis in a variety of
cancers.
Several studies have found an increased risk of developing
leukemia among the obese (8–11). In a meta-analysis of cohort
studies, Larsson and Wolk found that excess body weight is associ-
ated with an increased risk of developing all four major subtypes
of hematologic malignancies [ALL, acute myelogenous leukemia
(AML), chronic lymphocytic leukemia (CLL), and chronic myel-
ogenous leukemia (CML)] (12). They estimated that each 5 kg/m2
of increased BMI is associated with a 13% increase risk of devel-
oping leukemia. Others have shown that obesity increases the risk
of developing Hodgkin’s lymphoma, non-Hodgkin’s lymphoma,
and multiple myeloma (13–15).
The association between obesity and leukemia prognosis has
also been examined in many studies, with some detecting an effect
of obesity to worsen prognosis, and others not (Table 1). Two
of the studies acknowledged that their failure to detect an asso-
ciation between BMI and ALL outcome may have been due to
small sample size (16, 17). Interestingly, the risk estimates of over-
all survival and event-free survival from both studies showed a
trend of worsened outcome in the overweight/obese patients. The
largest study was done by the CCG, and included over 5000 chil-
dren (18). This study found that obesity was associated with a
significantly increased risk of relapse, particularly in children over
10 years of age (considered high risk). This latter caveat is consis-
tent with the findings of a relatively small study of 337 patients
from the UKALL X treatment trial, which included only stan-
dard risk patients, and concluded that overweight or obesity at
diagnosis was unlikely to impair prognosis (20). Thus, it appears
that obesity can impair ALL outcome at least in high risk, older
patients.
Since obesity is associated with many potential confounding
socioeconomic, genetic, behavioral, environmental, and treatment
factors, it is difficult to determine whether it is causally related to
leukemia development and prognosis, or rather associated with
some other prognostic variable. For example, a genetic or envi-
ronmental factor could in theory predispose some children to
develop both obesity and leukemia. Some studies have suggested
that obese patients may receive suboptimal care due to difficulty
performing basic physical and radiologic assessments, which could
contribute to poorer outcome (21, 22). While these possibilities
are difficult to tease apart in patients, Yun et al. performed a study,
which showed that diet-induced obesity directly accelerates ALL
progression in two mouse models (23). This was the first indica-
tion that the observed associations between obesity and leukemia
incidence are likely to be directly related to the biological effects
of obesity per se. However, the authors were not able to identify
any specific mechanisms responsible for this effect, though several
hormones, such as insulin, leptin, and IL-6, were elevated in the
obese mice.
ADIPOSE TISSUE
Adipose tissue is a major body constituent. Healthy men and
women are composed of ~8–19 and 21–33% fat, respectively (24).
Morbidly obese individuals can have well over 40% body fat. By
volume, adipocytes are the major cell type found in adipose tis-
sue. However,preadipocytes,fibroblasts, endothelial cells, immune
cells, adipose stem cells, and adipose tissue macrophages are also
found in adipose tissue (25–28). Particularly in obese individuals,
these other cell types can account for more than half of the number
of cells in adipose tissue.
Traditionally, adipose tissue has been recognized as primarily
a site for fuel storage. However, since the discovery of leptin by
Zhang et al. in 1994, it is now well-established that adipose tissue
is an active endocrine organ (29). There are now more than 50
identified adipokines (i.e., cytokines secreted primarily by adipose
tissue) (30). These adipokines regulate appetite, energy expendi-
ture, immune function, growth, and metabolism of other tissues.
Many adipokines (such as leptin) and other cytokines secreted
by adipose tissue (such as IGF-1), have been linked to cancer
pathogenesis.
Numerous immune cells are found in normal adipose tis-
sue, including T and B lymphocytes, NK cells, NKT cells, mast
cells, macrophages, and neutrophils. Adipose tissue inflamma-
tion likely contributes to many of the negative sequelae of obe-
sity, including diabetes, heart disease, and possibly cancer (31).
Obesity is associated with an increased number of lymphocytes
in adipose tissue in mice (12). These lymphocytes are believed
to interact with adipocytes and adipose tissue macrophages,
and may play a role in obesity-induced insulin resistance and
diabetes (32).
ADIPOCYTES IN THE CANCER MICROENVIRONMENT
Several cancers occur in close proximity to adipose tissue. Breast,
colon, pancreas, ovary, uterus, and liver are all surrounded by
and/or infiltrated by adipose tissue. Extension of these cancer types
outside of their originating organ often takes them into direct
contact with adipose tissue. Furthermore, adipocytes are found
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Table 1 | Retrospective studies examining the association between overweight/obesity and ALL outcome (EFS, event free survival; HR, hazard
ratio).
Study Population (age) Cooperative group/regimen No Results Conclusion
Baillargeon (16) Predominantly
Hispanic B-precursor
ALL patients
(2–9 years)
South Texas pediatric minority
based community clinical oncology
program/pediatric oncology group
legacy protocols
241 HR of obesity on
EFS=1.09 (0.54–2.20)
“No association between
obesity and survival”
Predominantly
Hispanic B-precursor
ALL patients
(10–18 years)
South Texas pediatric minority
based community clinical oncology
program/pediatric oncology group
legacy protocols
81 HR of obesity on
EFS=1.48 (0.73–3.01)
Hijiya (17) Predominantly white
ALL
St Jude total therapy studies/total
XII, XIIIA, XIIIB, and XIV
621 5 year EFS:
obese=72.7±5.9%,
normal
weight=78.7±2.1%,
p=0.722
“No association between BMI
and outcome or toxicity in
children with ALL”
Subset ≥10 years St Jude total therapy studies/total
XII, XIIIA, XIIIB, and XIV
185 p=0.103 For effect of
obesity on EFS
“Relatively small number of
patients and the use of different
treatments compared to those of
the CCG study”
Butturini (18) Predominantly white
newly diagnosed
ALL
CCG1881
CCG1922
CCG1891
CCG1882
CCG1901
4260 HR of obesity on events
1.26 (1.03–1.55),
p=0.02
“In this study, obesity seems to
be one of the main determinants
of relapse in . . . patients
diagnosed with ALL after their
10th birthday . . .”
Predominantly white
newly diagnosed
ALL (≥10 years)
CCG1882
CCG1901
1003 HR of obesity on events
1.48 (1.07–2.03),
p=0.01
Verification cohort
(≥10 years)
CCG1961 1160 Obese and ≥10 years
old: 1.42 (1.03–1.96)
p=0.032
Gelelete (19) Children with ALL
(mainly <10 years)
IPPMG/UFRJ/Berlin–Frankfurt–
Munich protocols
181 HR of overweight and
obese on EFS 1.92
(1.42–2.6) p=0.031
“. . . Overweight or obesity at
diagnosis was an independent
prognostic factor to the 5-years
EFS in children with ALL . . .”
Aldhafiri (20) UK national cohort
excluding high risk
and low risk
(2–15 years)
UKALL X treatment trial 337 Relapse rate in over-
weight/obese=36.2%,
healthy weight=36.6%
“No evidence that being
overweight/obese at diagnosis
impairs prognosis in childhood
ALL in the UK”
in the bone marrow, a common site for solid tumor metastasis
(33), and an important microenvironment for many hematologic
malignancies (34). Bone marrow adiposity is not only affected
by obesity (35), but has recently been shown to be influenced by
ALL treatment (36). Vicente López et al. isolated mesenchymal
stem cells (MSCs) from bone marrow aspirates of ALL patients at
various timepoints: diagnosis, during therapy, and after therapy.
ALL-MSC from treated patients showed an increased adipogenic
differentiation potential, including a higher expression of adi-
pogenic genes (CEBP and PPARgamma), compared to healthy
MSC (36).
Given the fact that lymphocytes infiltrate adipose tissue, it
is not surprising that adipocytes attract preB leukemia cells as
well. We found that ALL cells were present in adipose tissue of
mice, which developed progressive leukemia despite vincristine
treatment (37). In addition, syngeneic ALL cells implanted into
mice by a retro-orbital injection infiltrated adipose tissue within
10 days, to a similar degree as other more classic sites for ALL,
such as spleen and liver (38). ALL migration toward adipocytes is
mediated by adipocyte secretion of stromal cell-derived factor 1
alpha (SDF-1α or CXCL12). While obesity was not associated with
increased serum levels of SDF-1α, obese mice had a significantly
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higher burden of leukemia cells in visceral fat compared to con-
trol mice (38). Adipocytes have been shown by others to facilitate
leukemia bone marrow engraftment via secretion of SDF-1α and
leptin (39). Adipocytes also promote invasion of a number of other
cancer types, including ovarian, gastric, breast, and colon (40, 41).
Some cancer cells directly interact with adipocytes and induce
a phenotypic change, turning them into “cancer associated
adipocytes” (CAA) (41), though this has not to our knowledge
been observed in leukemia. Reprogramed adipocytes provide
growth factors and fuel to cancer cells, promoting metastasis,
and sustaining uncontrolled growth. Ribeiro et al. have shown
that peri-prostatic adipose tissue explants from overweight/obese
prostate cancer patients had significantly elevated MMP9 activity,
which is correlated with disease progression and metastasis (42). In
breast cancer, adipocyte-derived collagen IV (43) and endotrophin
(44) have been shown to promote tumor progression.
ADIPOSE TISSUE PROVIDES FUEL FOR ALL CELLS
One of the hallmarks of cancer is rapid proliferation, which
requires a high amount of energy and nutrient building blocks.
A major function of adipocytes is energy storage in the form of
triglycerides, which can be broken down into glycerol and free fatty
acids (FFA) and released in a process termed lipolysis. Therefore,
it is possible that adipocytes provide FFA to cancer cells, facili-
tating their energy demands and contributing to their synthesis
of lipid moieties such as phospholipid membranes and signaling
molecules. Indeed, many cancer cell types have been shown to
have lipid droplets, which may represent important energy stores
(40, 45, 46).
There is recent evidence of adipocytes providing FFA as fuel
source to leukemia cells. A recent paper by Tung et al. found
that FFAs could support CLL metabolism and cause resistance
to glucocorticoid-mediated cytotoxicity (47). They showed both
adipocyte-conditioned media (ACM) and heat-inactivated ACM
were able to reduce dexamethasone-induced CLL cell death, sug-
gesting the factors in ACM to be lipids. However, there was no
evidence of direct transfer of lipids from adipocytes to CLL. Tucci
et al. have found evidence that ALL cells stimulate adipocyte
lipolysis and use adipocyte-derived FFAs to supplement de novo
lipogenesis and proliferation (48). Other cancer cell types, such as
breast and ovarian cancer, have also been shown to induce lipolysis
and dedifferentiation of nearby adipocytes (31, 40, 41).
Adipocytes also produce amino acids. Adipose tissue is a major
source of glutamine, an important fuel for cancer cells, and a
building block needed for synthesis of nucleic acids and pro-
teins. l-asparaginase is used in ALL treatment because leukemic
lymphoblasts are exquisitely sensitive to the depletion of exoge-
nous asparagine and glutamine (49, 50). The drug hydrolyzes
asparagine and glutamine to aspartic acid and glutamic acid,
respectively. A recent paper by Ehsanipour et al. reported that
adipocytes protect leukemia cells from l-asparaginase treatment
by producing asparagine and glutamine (51). The authors treated
leukemic diet-induced obese (DIO) and normal weight C57Bl/6
mice with the drug proportional to body weight and found signif-
icantly shortened survival in the DIO mice. An increase in both
glutamine synthetase and adipocyte number was observed in bone
marrow biopsy specimens from adolescent leukemia patients after
induction treatment. Adipocyte protection of ALL cells against
l-asparaginase was blocked by pretreatment with an inhibitor of
glutamine synthetase. Since leukemia cells can infiltrate adipose
tissue, it is possible that high local levels of these amino acids
protects ALL cells from l-asparaginase.
ADIPOSE TISSUE ALTERS CHEMOTHERAPY
PHARMACOKINETICS
Obesity influences many aspects of drug pharmacokinetics (PK).
For lipid-soluble drugs, obesity increases the volume of distribu-
tion by accumulation of drug in the excess adipose tissue (52–54).
Obesity is also associated with increased alpha 1-acid glycopro-
teins, which could increase the binding of basic drugs in plasma
(53). Hepatic and renal drug clearance could be altered in obesity
due to increased activity of cytochrome P450 2E1 and increased
glomerular filtration and tubular secretion (55, 56). This in turn
could alter the PK of water-soluble drugs, since they can be readily
excreted from the kidneys (57). Since the overall exposure to a
drug depends on both the volume of distribution and the clear-
ance, obesity could be associated with both toxicity and impaired
efficacy of different medications. While there have been no stud-
ies of which we are aware examining the effects of weight status
on PK in children with leukemia, a retrospective study by Hijiya
et al. reported no difference in mean systemic clearance and
intracellular levels of thioguanine nucleotides and methotrexate
polyglutamates among four BMI groups. (17).
Vincristine, a potent anti-microtubule agent, is a key drug used
in childhood ALL combination chemotherapy, as well as treatment
of many other cancers. In pediatric and adult leukemia patients,
vincristine is dosed proportional to body surface area, and this
dose is generally “capped” at 1 square meter. We found that DIO
mice implanted with syngeneic leukemia cells exhibited poorer
survival compared to control mice, despite vincristine treatment
being dosed proportional to body weight (37). However, there
have been few PK studies examining the impact of obesity on
chemotherapy treatments. Given that vincristine is a lipophilic
agent, it may be sequestered in adipose tissue and thus have altered
tissue distribution in obese individuals. We explored this idea using
injections of tritiated vincristine in obese and control mice (58).
Upon a single intravenous injection of vincristine proportional to
body weight, blood and tissue levels of the drug were measured
at different time points up to 24 h. Over the initial 24 h, blood
vincristine concentrations were higher in the obese mice than the
control, while tissue concentrations were comparable in spleen,
liver, brown fat, and bone marrow. However, by 3 h, there was sig-
nificantly higher vincristine in the white adipose tissue of obese
mice than that of control mice. PK modeling showed that overall
exposure of ALL cells to vincristine is impaired by obesity, and this
may be exacerbated when the drug is dosed/body surface area and
is capped.
In 2012, the American Society of Clinical Oncology published
recommendations for appropriate cytotoxic chemotherapy dosing
for obese adult cancer patients (59). The ASCO assembled a panel
of experts to conduct a systematic review of studies published
between 1996 and 2010. They reported that up to 40% of obese
patients received reduced chemotherapy doses that were not based
on actually body weight. Meanwhile, they found no evidence that
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short- or long-term toxicity was increased among obese patients
receiving full weight-based doses. The panel thus recommends that
“full weight-based chemotherapy doses be used in the treatment
of the obese patient with cancer, particularly when the goal of
treatment is cure.”
ADIPOSE TISSUE PREVENTS LEUKEMIA APOPTOSIS
There is growing evidence that adipocytes and other cells found
in adipose tissue provide survival advantages to cancer cells in the
face of chemotherapy. Using an in vitro TransWell co-culture sys-
tem, Behan et al. have shown that adipocytes protect ALL cells from
vincristine, nilotinib, daunorubicin, and dexamethasone (37). The
authors found that adipocyte protection of ALL cells from vin-
cristine was associated with upregulation of Bcl-2 and Pim-2 (both
pro-survival signals in the intrinsic apoptosis pathway), and an
increased phosphorylation of Bad (indicating inactivation of the
pro-apoptotic protein). Beaulieu et al. reported that leptin from
adipocytes can reverse pro-apoptotic and antiproliferative effects
of alpha-linolenic acids in BCR-ABL chronic myeloid leukemia
cells (60). In a separate study, MSC-derived adipocytes protected
acute promyelocytic leukemia cells from apoptosis induced by
serum starvation or by doxorubicin, possibly partially by leptin
(61). Adipocytes have also been reported to cause chronic lym-
phoblastic leukemia cells to become resistant to dexamethasone
by providing lipid factors (47).
A series of experiments published by Iyengar et al. demon-
strated that adipocytes could induce both replicative potential and
evasion of apoptosis in breast cancer cells (62). An upregulation
of A20 and NFkB, both anti-apoptotic signals, was seen in MCF-7
breast cancer cells treated with ACM, suggesting a direct effect of
adipokines on the cancer cells.
One of the adipokines that is elevated in obesity is leptin, which
has been shown to promote the growth of several types of cancer.
Adipose tissue is the main source of leptin secretion; however, nor-
mal and malignant breast tissue has been reported to also secrete
leptin. Interestingly, high leptin and low adiponectin have been
reported in children with ALL compared to age, sex, and BMI
matched healthy controls (63). These findings are consistent with
the evidence that leptin has proliferative effects on hematopoietic
cells (64, 65), while adiponectin has a protective role against car-
cinogenesis (66–68). Leptin receptor mRNA has been detected in
several myeloid and lymphoid leukemic cell lines, including some
newly diagnosed cases of AML, ALL, and CML during blast crisis
(69, 70). Leptin has been shown to be involved in the pathogenesis
of breast and prostate cancers as well (71, 72).
Not only do adipocytes play an important role in the tumor
microenvironment, adipose tissue stromal cells (ASC) have been
shown to be recruited to tumors and enhance tumor vasculariza-
tion, and promote survival and proliferation of the tumor cells
(73, 74). These ASC have many features of bone marrow-derived
mesenchymal stromal cells (75), including cell surface marker
expression (76), plastic adherence (77), and the capacity to differ-
entiate into osteoblasts, chondrocytes, and adipocytes (78). While
ASCs have not been studied in the context of leukemia, they have
been shown to promote the growth of human endometrial adeno-
carcinoma xenografts in immunodeficient nude mice, likely due
to increasing vascularization (79).
POTENTIAL THERAPEUTIC TARGETS TOWARD DRUG
RESISTANCE ASSOCIATED WITH OBESITY
With the prevalence of obesity and the mounting evidence of
increased adiposity as a risk factor for cancer incidence and
mortality, it is important to understand the adipocyte-cancer
interaction and expand traditional therapies to address obesity.
More than two decades ago, Shields et al. showed that chronic
energy-intake restriction (CEIR) has profound effects to delay
lymphoma development in AKR mice (80). As a more practical
strategy than CEIR, short-term fasting has been demonstrated
to provide differential stress resistance to chemotherapy, where
normal cells are protected while cancerous cells remain sensitive.
There is evidence that fasting is not only safe, but also effective in
reducing common side effects associated with chemotherapy (81).
There are a number of clinically available metabolic agents
targeting adipocyte differentiation, insulin resistance, and inflam-
mation that have been shown to have anti-cancer effects. One of
such agents is metformin, which is clinically used to treat type
2 diabetes mellitus. While metformin has not been testing in
leukemia patients, analysis of a retrospective cohort of 363 women
diagnosed with endometrial cancer and diabetes mellitus analysis
demonstrated that metformin use was associated with prolonged
recurrence-free survival time (82).
Since adipocytes may be providing cancer cells with FFA as a
fuel source, inhibition of lipolysis, and FFA efflux from adipocytes
or blocking of cancer cell FFA oxidation could represent thera-
peutic targets. Inhibition of FFA oxidation, such as with etomoxir,
has been shown to impair a variety of hematological malignancies,
including myeloma cell (83), AML (84), CLL (85), and mantle cell
lymphoma (86). Since cancer cells, such as ovarian cancer, increase
their FFA oxidation rate when co-cultured with adipocytes (40),
targeting this pathway may be particularly beneficial in obese
patients.
CONCLUSION AND PERSPECTIVE
Over the past two decades, there has been ground-breaking
research in the field of adipocyte biology, leading to a reassessment
of the role of adipose tissue in man. There has also been mount-
ing epidemiological evidence of the important effect of obesity on
cancer incidence and mortality. Adipocytes play an active role in
the tumor microenvironment in many types of cancer, including
those that have strong associations with obesity. With obesity rates
reaching unprecedented levels worldwide and the alarming rise in
childhood obesity, teasing apart the mechanisms linking obesity,
and cancer represents a crucial step in the quest to improve overall
cancer survival.
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